Cargando…
Metabolism remodeling in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of death of patients with malignant cancers by 2030. Current options of PDAC treatment are limited and the five-year survival rate is less than 8%, leading to an urgent need to explore innovatively therapeutic st...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Shared Science Publishers OG
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883744/ https://www.ncbi.nlm.nih.gov/pubmed/31832601 http://dx.doi.org/10.15698/cst2019.12.205 |